© 2021 MJH Life Sciences and Gene Therapy Live. All rights reserved.
© 2021 MJH Life Sciences™ and Gene Therapy Live. All rights reserved.
September 14, 2021
RGX-314 is being developed to target wet AMD, diabetic retinopathy, and other chronic retinal diseases.
July 30, 2021
Investigators found that reactivating the CaMKII enzyme could protect against further vision loss.
July 24, 2021
MCO-010 is designed to deliver multi-characteristic opsin to retinal cells.
June 03, 2021
Nanoscope Therapeutics Inc. expects to advance the therapy by launching a late-stage Phase 2b trial this summer with gene therapy that delivers multi-characteristic opsin to retinal cells.